STOCKS IN THIS WATCHLIST ARE GENERALLY GEARED TOWARDS SWING TRADING BUT CAN ALSO BE USED FOR DAY OR LONG TRADES. STOCKS ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE ACCOMPANYING CHARTS. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com or wsj.com).
Stocks highlighted in this watchlist include: $AGEN, $ATHX, $ATNX
AGEN: Float of 51.27 million shares with 20.07% short.
On Nov. 15, 2017 AGEN, an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced the receipt of a $4 million payment for the advancement of an undisclosed antibody under the license and research collaboration agreement with Merck, known as MSD outside the United States and Canada. As previously announced, Merck is responsible for all future product development expenses for the selected antibody and Agenus is eligible to receive up to an additional $99 million in milestone payments, as well as royalties on worldwide product sales.
ATHX: Float of 115.82 million shares with 7.55% short.
Last week, ATHX announced that its partner, HEALIOS K.K. (“Healios”), has enrolled the first patient in its study in Japan evaluating MultiStem® cell therapy treatment of patients who have suffered an ischemic stroke (the “TREASURE” study). The TREASURE study is designed to enroll a total of 220 patients with moderate to severe strokes and will be randomized 1:1, with patients receiving a single intravenous infusion of MultiStem or placebo within 18 to 36 hours of the onset of the stroke.
ATNX: Float of 33.8 million shares with 4.66% short.
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced Johnson Lau, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 29, 2017 at 1:00 pm EST.
On Monday, ATNX announced positive interim analysis results of an Oraxol pharmacokinetic (PK) study titled “Open-label, randomized cross-over bioavailability study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors”. Patients treated with Oraxol demonstrated exposure that was comparable to IV paclitaxel and an encouraging safety profile without grade 3-4 toxicities, according to findings from this study presented at ESMO Asia 2017 in Singapore, an Annual Congress organized by the European Society for Medical Oncology.
The Phase 3 Interim data for Oraxol for Metastatic breast cancer is due late 2017.